“Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of ...

The MarketWatch News Department was not involved in the creation of this content. -- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of ...

The blood–brain barrier functions as an evolutionarily optimized vascular “filter,” permitting limited penetration of small molecules like temozolomide while effectively excluding most biologics from ...

A modified herpes virus boosted immune T cell infiltration in glioblastoma tumors and was associated with improved survival.

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

The FDA approved a pilot study for Alpha DaRT, targeting recurrent glioblastoma with alpha-radiation therapy. Alpha DaRT uses radium-224 to deliver focused radiation to tumors, sparing healthy tissue.

Please provide your email address to receive an email when new articles are posted on . Although the objective response rate exceeded the prespecified control rate, it fell short of achieving the ...

Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, which mobilize the body's ...

Please provide your email address to receive an email when new articles are posted on . The addition of an autologous tumor lysate-loaded dendritic vaccine to standard care extended OS among certain ...

May 6, 2009 — The US Food and Drug Administration (FDA) has granted accelerated approval for bevacizumab (Avastin, Genentech) for use in patients with glioblastoma that has progressed despite previous ...